Catawba Capital Management VA Acquires 190 Shares of Becton Dickinson and Co. (BDX)
Catawba Capital Management VA raised its position in Becton Dickinson and Co. (NYSE:BDX) by 0.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,282 shares of the company’s stock after buying an additional 190 shares during the period. Becton Dickinson and accounts for about 1.9% of Catawba Capital Management VA’s holdings, making the stock its 6th largest position. Catawba Capital Management VA’s holdings in Becton Dickinson and were worth $7,959,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Jarislowsky Fraser Ltd boosted its position in Becton Dickinson and by 1,050.3% in the second quarter. Jarislowsky Fraser Ltd now owns 10,373,430 shares of the company’s stock worth $531,241,000 after buying an additional 9,471,594 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Becton Dickinson and by 64.3% in the second quarter. JPMorgan Chase & Co. now owns 3,779,957 shares of the company’s stock worth $641,043,000 after buying an additional 1,479,124 shares during the last quarter. Prudential Financial Inc. boosted its position in Becton Dickinson and by 278.3% in the second quarter. Prudential Financial Inc. now owns 1,029,329 shares of the company’s stock worth $174,563,000 after buying an additional 757,251 shares during the last quarter. Bank of Montreal Can acquired a new position in Becton Dickinson and during the second quarter worth approximately $118,746,000. Finally, Emerald Acquisition Ltd. acquired a new position in Becton Dickinson and during the second quarter worth approximately $102,860,000. Institutional investors and hedge funds own 82.68% of the company’s stock.
Shares of Becton Dickinson and Co. (NYSE:BDX) traded up 0.12% on Monday, reaching $172.07. 896,767 shares of the company’s stock traded hands. The firm has a market cap of $36.64 billion, a P/E ratio of 38.32 and a beta of 1.04. Becton Dickinson and Co. has a one year low of $129.50 and a one year high of $181.76. The company’s 50-day moving average price is $172.43 and its 200 day moving average price is $172.32.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 3rd. The company reported $2.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.09 by $0.03. Becton Dickinson and had a net margin of 7.82% and a return on equity of 24.44%. The firm earned $3.23 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the prior year, the firm earned $1.94 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. On average, equities analysts forecast that Becton Dickinson and Co. will post $9.52 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be given a dividend of $0.73 per share. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.70%. Becton Dickinson and’s dividend payout ratio is currently 58.54%.
BDX has been the subject of a number of research analyst reports. Citigroup Inc. cut Becton Dickinson and from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $167.00 to $165.00 in a report on Friday, September 23rd. Cowen and Company restated an “outperform” rating and set a $185.00 price objective on shares of Becton Dickinson and in a report on Tuesday, August 16th. Jefferies Group restated a “buy” rating on shares of Becton Dickinson and in a report on Friday, August 5th. Zacks Investment Research cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, November 16th. Finally, Leerink Swann restated a “market perform” rating and set a $185.00 price objective (up previously from $180.00) on shares of Becton Dickinson and in a report on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $176.11.
In other news, insider Linda M. Tharby sold 11,704 shares of the stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $177.27, for a total transaction of $2,074,768.08. Following the completion of the transaction, the insider now directly owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Stephen Sichak sold 10,352 shares of the stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $176.10, for a total transaction of $1,822,987.20. Following the transaction, the insider now directly owns 26,892 shares of the company’s stock, valued at $4,735,681.20. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Receive News & Stock Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related stocks with our FREE daily email newsletter.